Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
Polyrizon Ltd., a Nasdaq-listed pre-clinical-stage biotech company specializing in intranasal hydrogel medical devices, announced the filing of its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. SEC. The report details their development progress in their proprietary Capture and Contain™ hydrogel technology and …